Jan 08, 2025 8:00 am EST Mineralys Therapeutics Announces Phase 2 Clinical Trial of Lorundrostat for Obstructive Sleep Apnea in Patients with Hypertension
Nov 11, 2024 4:05 pm EST Mineralys Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update
Nov 04, 2024 4:05 pm EST Mineralys Therapeutics to Announce Third Quarter 2024 Financial Results and Host Conference Call on Monday, November 11, 2024
Oct 30, 2024 8:00 am EDT Mineralys Therapeutics Completes Enrollment Ahead of Schedule in Launch-HTN, the Second Pivotal Trial of Lorundrostat for the Treatment of Hypertension
Oct 22, 2024 8:00 am EDT Mineralys to Host Virtual KOL Event on the Unmet Medical Need in Uncontrolled and Resistant Hypertension, and Lorundrostat as a Potential Treatment on October 30, 2024
Sep 25, 2024 8:00 am EDT Mineralys Therapeutics Completes Target Enrollment in Pivotal Advance-HTN Trial of Lorundrostat for the Treatment of Hypertension
Aug 28, 2024 8:00 am EDT Mineralys Therapeutics to Participate in the Wells Fargo Healthcare Conference
Aug 13, 2024 4:05 pm EDT Mineralys Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update
Aug 05, 2024 4:05 pm EDT Mineralys Therapeutics to Announce Second Quarter 2024 Financial Results and Host Conference Call on Tuesday, August 13, 2024
